CA-GILEAD-SCIENCES-INC
10.10.2019 22:07:04 CEST | Business Wire | Press release
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2019 financial results will be released on Thursday, October 24, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2019 and provide a business update.
The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/ . Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 6094972 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, October 26, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID 6094972. The webcast will be archived on www.gilead.com for one year.
About Gilead
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191010005026/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MultiBank Group Named Forex Broker of the Year 2026 at Money Expo Abu Dhabi16.7.2026 13:35:00 CEST | Press release
MultiBank Group, one of the world's largest and most regulated online financial derivatives institutions, has been named Forex Broker of the Year at Money Expo Abu Dhabi. The event was held on 8–9 July 2026 at the ADNEC Centre. This flagship award recognizes the broker setting the benchmark for excellence across the global trading and fintech industry. MultiBank Group's participation in the expo underscored its leadership position within the Middle East's financial landscape. A Landmark Event for Trading and Fintech Money Expo Abu Dhabi 2026 brought together traders, banks, fintech firms, liquidity providers, and market leaders from across the region and beyond. Winning top honors on this stage sends a clear signal across the entire industry. “Being named Forex Broker of the Year is a defining moment for our Group,” said Johny Giacaman, Chief Business Operations Officer at MultiBank Group. “It reflects two decades of regulatory discipline, technological innovation, and an unwavering co
illumynt Appoints Anthony Giannetti as Senior Vice President of Global Operations16.7.2026 13:00:00 CEST | Press release
Seasoned operations leader brings two decades of OEM and ITAD experience, including Dell, Apple, and Microsoft, as illumynt scales its global AI hardware lifecycle platform illumynt, a technology-driven leader in AI hardware lifecycle recovery and IT asset disposition (ITAD), today announced that Anthony "Tony" Giannetti has joined the company as Senior Vice President of Global Operations, effective July 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716696044/en/ Anthony Giannetti, SVP Global Operations Giannetti brings more than two decades of operations and supply chain leadership from some of the technology industry's largest OEMs, including Dell, where he managed reverse supply chain operations, and Apple and Microsoft, where he held additional operations leadership roles. His background spans production engineering, reverse logistics, and large-scale operational management, disciplines directly relevant to
Compvide™ Announces Strategic Collaboration with OpZira™ to Accelerate Growth and Advance the CIMED™ Platform16.7.2026 12:47:00 CEST | Press release
Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collaboration with OpZira, Inc. to support the company’s continued growth and accelerate development of its proprietary CIMED platform. Through the collaboration, OpZira will provide comprehensive operational support across clinical, customer care, finance, manufacturing, marketing, quality, and regulatory functions,” stated Clark Tedford, Ph.D., President and CEO, OpZira, Inc. “By leveraging OpZira’s established operational infrastructure and expertise, Compvide can remain focused on advancing its scientific innovation while expanding its capabilities in complement-focused diagnostics and translational medicine.” “Partnering with an experienced organization that understands the unique needs of emerging healthcare companies is an important step for Compvide as we continue building the company,” said Sadam Yaseen
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy16.7.2026 12:35:00 CEST | Press release
Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapyFindings published in the Journal of Psychopharmacology Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment administration sessions showed minimal interaction. Monitoring and support were linked by patients to presence, availability, reassurance and validation. The limited and non-directive nature of these interactions distinguishes this fo
Circus Commences Operations with Ukrainian Ground Forces16.7.2026 12:04:00 CEST | Press release
Circus SE (WKN: A2YN35 / ISIN: DE000A2YN355 / XETRA: CA1), today announces the commencement of live operations of its robotic-based troop supply technology with the 3rd Army Corps of the Ukrainian Ground Forces in the Kyiv area – marking the first ever use of autonomous meal supply systems within an active conflict environment. Ahead of deployment, Circus received regulatory certification from the State Service of Ukraine for Food Safety and Consumer Protection. This certification confirms compliance with all applicable health, quality, and safety standards required to import the company's technology into Ukraine, and clears the path for operational use at scale. Soldiers are supplied using Circus's full technology stack, comprising the hardware system, AI-controlled software, and proprietary ingredient infrastructure that underpins autonomous meal production in military environments. The deployment marks Circus's entry into the Ukrainian market and the operational commencement of the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom